Patent · US Active

Compositions and methods for detecting EGFR in cancer

US10000568B2 · kind B2 · utility

0Cited by

2References

5Claims

0Family size

Assignee

CELL SIGNALING TECHNOLOGY, INC. · US

Inventors

Ting-Lei Gu · Woburn, US
Jiong Wu · Los Gatos, US
Susan Kane · Beverly, US
Jian Yu · New Providence, US
Herbert Haack · Hamilton, US
James Wieler · Beverly, US
Jun-Ming Cai · Hamilton, US
Victoria McGuinness Rimkunas · Somerville, US

Key dates

Filing date	Apr 10, 2009
Grant date	Jun 19, 2018
Priority date	—
Expiry date	Mar 12, 2031

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/52
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

The invention discloses binding agents to the E746-A750 deletion and the L858R point mutations in the epidermal growth factor receptor (EGFR) molecule, and methods for use thereof, including methods for the diagnosis and treatment of cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.